Specialty medical-device manufacturer Amendia Inc. will invest up to $50 million to commercialize a biomedical spinoff that focuses on implant technology and stem cell therapies. The new venture, Vivex Biomedical Inc., is developing implant technology to help stimulate bone regrowth. Vivex has also licensed a highly adaptive adult stem cell line, known as MIAMI (Marrow Isolated Adult Multi-lineage Inducible) cells.
